News

"The orphan drug designation for XOMA 358 recognizes its potential to address a significant unmet medical need for patients with congenital hyperinsulinism. Patients with hyperinsulinism, a rare and

This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with

Currently, PUR0200 is being evaluated for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from Pulmatrix’s new iSPERSE inhaled dry powder technology. PUR0200, which contains

Both these HPV types are responsible for 70% of cervical cancer cases and currently there are no treatment options available for the 93 million women worldwide infected with

Founders Giorgos Tsetis, a fashion model and engineer and Roland Peralta, a beauty and fashion executive suffered from hair loss and sought integrative and holistic solutions. They assembled

A first for the company, the new supplement contains the well-researched and highly efficacious probiotic strain, Lactobacillus plantarum 299v (LP299V), which can withstand the stomach’s acidic environment allowing

The products meet all U.S. regulatory requirements. The highly popular Superburn and T-300 have long appealed to consumers interested in safe and effective ways to manage their weight,

Earlier, the agency has accepted the company’s investigational new drug (IND) application for a Phase I/II open-label, dose-escalating trial of PRTX-100 in adults with persistent/chronic ITP. The company

Dextenza (sustained release dexamethasone, 0.4mg) is administered by a physician as a bioresorbable intracanalicular depot for drug release to the ocular surface for up 30 days. People who